Skip to content

A single center and non inferiority clinical study program for the Decrustation ointment treatment of deep II degree burn with random, single blind and blind evaluation, positive drug self control

A single center and non inferiority clinical study program for the Decrustation ointment treatment of deep II degree burn with random, single blind and blind evaluation, positive drug self control

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008208
Enrollment
Unknown
Registered
2016-04-01
Start date
2016-04-05
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

burn

Interventions

A:left(up):Decrustation Ointment right(below):Intrasite Gel
B:left(up):Intrasite Gel right(below):Decrustation Ointment

Sponsors

Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Deep II degree burn patients, the overall surface area (TBSA) 1-30%, can be observed on a single wound is not less than 50-100cm2, not greater than TBSA 10%; 2. Aged 15-70 years old, men and women are not limited; 3. Outpatient or inpatient, within 7 days after the injury to the hospital; 4. Women of childbearing age should have effective contraceptive methods during the trial period; 5. Patients fully understand and voluntarily sign informed consent; 6. Be able to comply with the test requirements and be able to complete all follow up.

Exclusion criteria

Exclusion criteria: 1. Allergy or hypersensitivity to the known components of the formulation; 2. Diabetes mellitus, malignant tumor, chronic wasting disease; 3. Patients with severe heart, liver, kidney and blood system complications; 4. Vascular lesions of the extremities; 5. At the same time using Recombinant Human Epidermal Growth Factor Gel as a wound treatment of patients with drugs; 6. Patients with immune disorders or application of hormone drugs; 7. Female patients who are pregnant or breastfeeding or who are prepared to be pregnant during the trial; 8. The researchers believe that the patient's previous or current physical or mental condition is likely to be dangerous in the course of the trial, interfere with the test evaluation or interfere with the patient to participate in the test; 9. In severe and difficult to control the local or systemic acute and chronic infection period; or the history of active tuberculosis or in the treatment of tuberculosis patients; 10. Clinical trials of patients attending other drugs or devices within 30 days; 11. Other conditions that the researchers considered were not appropriate for the trial.

Design outcomes

Primary

MeasureTime frame
Healing of wound area ratio;

Secondary

MeasureTime frame
Wound healing days;The ratio of necrotic tissue area and the area of the wound;The ratio of wound infections;Pain Grade;

Countries

China

Contacts

Public ContactZhuo Wang

Changhai Hospital

wangzhuo088@163.com+86 13818390863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026